Key facts
- It has raised $5.9M; the latest was Accelerator/Incubator in Sep 2024.
- Notable investors include Creative Destruction Lab, University of Toronto, Endless Frontier Labs, University of Toronto Entrepreneurship, Berkeley SkyDeck — 28 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 28 names
- ·Watchlist + deal alerts for HDAX Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for HDAX Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About HDAX Therapeutics
Developer of small molecule therapeutics intended for the treatment of HDAC6-driven pathologies such as neuropathies and cardiometabolic diseases. The company focuses on creating a targeted therapeutics platform based on a differentiated two-site binding mechanism for HDAC6 for the delivery of a safe, efficacious, and long-lasting treatment of diseases, enabling clinical researchers to pursue novel therapies with refined accuracy and enhanced treatment potential.
- Sector
- Healthcare
- HQ
- Toronto, Canada
- Founded
- 2021
- Employees
- 9
- Website
- hdaxtx.com/
- Ownership
- Privately Held (backing)
HDAX Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HDAX Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on HDAX Therapeutics in its N-PORT filings yet. We sweep new filings monthly.